The hemodynamically significant patent ductus arteriosus (hsPDA) is a controversial topic in
neonatology, particularly among neonates at the earliest gestational ages of 22+ 0-23+ 6 …

The persistence of a patent ductus arteriosus (PDA) is a common condition in preterm
infants with a prevalence inversely proportional to gestational age. PDA is associated with …

Importance Bronchopulmonary dysplasia (BPD) is often associated with pulmonary vascular
disease and secondary pulmonary hypertension (PH). The pathogenesis of BPD-associated …

Importance Transcatheter closure of the patent ductus arteriosus (PDA) is being increasingly
adopted as an alternative to surgical PDA closure in preterm infants. Objective To develop …

Monitoring the growth of neonates in the Neonatal Intensive Care Unit (NICU) using growth
charts constitutes an essential part of preterm infant care. Preterm infants are at increased …

Background Pharmacologic therapy for patent ductus arteriosus closure is not consistently
successful. Surgical ligation (SL) or transcatheter closure (TC) may be needed. Large …

We evaluated changes in patent ductus arteriosus (PDA) diagnosis and treatment from 2012
through 2021 in a network of US academic hospitals. PDA treatment decreased among …

Objective This study describes 3-year follow-up of 200 infants weighing≥ 700 grams who
underwent transcatheter patent ductus arteriosus (PDA) closure with the Amplatzer …

Background: Very preterm birth often results in the development of bronchopulmonary
dysplasia (BPD) with an inverse correlation of gestational age and birthweight. This very …

To evaluate national epidemiologic data on infants treated for patent ductus arteriosus
(PDA) in Korea and analyze outcomes associated with different PDA treatments. We …